Nicox SA Stock price

Equities

ALCOX

FR0013018124

Pharmaceuticals

Real-time Euronext Paris 11:30:49 2024-03-28 am EDT 5-day change 1st Jan Change
0.397 EUR +1.79% Intraday chart for Nicox SA +1.15% -10.18%
Sales 2023 4.2M 4.53M Sales 2024 * 8.8M 9.49M Capitalization 19.5M 21.04M
Net income 2023 * -15M -16.18M Net income 2024 * -13M -14.02M EV / Sales 2023 5.25 x
Net Debt 2023 * 9.24M 9.97M Net cash position 2024 * - 0 EV / Sales 2024 * 2.22 x
P/E ratio 2023 *
-1.3 x
P/E ratio 2024 *
-1.86 x
Employees 28
Yield 2023 *
-
Yield 2024 *
-
Free-Float 93.36%
More Fundamentals * Assessed data
Dynamic Chart
1 week-0.64%
Current month-4.06%
1 month-6.92%
3 months-6.14%
6 months-4.76%
Current year-11.76%
More quotes
1 week
0.38
Extreme 0.381
0.40
1 month
0.37
Extreme 0.365
0.44
Current year
0.37
Extreme 0.365
0.49
1 year
0.30
Extreme 0.3
0.92
3 years
0.30
Extreme 0.3
4.49
5 years
0.30
Extreme 0.3
6.27
10 years
0.30
Extreme 0.3
13.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 04-12-31
Founder 70 96-02-14
Director of Finance/CFO 56 98-12-31
Members of the board TitleAgeSince
Director/Board Member 73 14-09-30
Director/Board Member 65 17-05-17
Director/Board Member 69 14-08-07
More insiders
Date Price Change Volume
24-03-28 0.397 +1.79% 42 476
24-03-27 0.39 0.00% 27,711
24-03-26 0.39 -2.01% 32,711
24-03-25 0.398 +0.25% 50,260
24-03-22 0.397 +1.15% 26,079

Real-time Euronext Paris, March 28, 2024 at 07:58 am EDT

More quotes
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The Company is also conducting research on NCX 1728 in retinal conditions. NCX 4251 for topical ocular application for dry eye disease is being developed by Nicox's licensed partner Ocumension Therapeutics in China and is available for partnering elsewhere. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow Health, Inc. in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets."
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.39 EUR
Average target price
1 EUR
Spread / Average Target
+156.41%
Consensus
  1. Stock
  2. Equities
  3. Stock Nicox SA - Euronext Paris